A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg Muco-Adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.

Trial Profile

A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg Muco-Adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Aciclovir (Primary)
  • Indications Herpes labialis
  • Focus Registrational; Therapeutic Use
  • Acronyms LIP
  • Most Recent Events

    • 24 Feb 2016 According to a Cipher Pharmaceuticals media release, Sitavig was accepted for review by Health Canada.
    • 03 Jul 2012 Planned number of patients changed from 1900 to 1950 as reported by European Clinical Trials Database.
    • 14 Dec 2009 Secondary endpoint 'Clinical response rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top